Scholarlink

Background <p>Upper gastrointestinal endoscopy often causes discomfort and anxiety, requiring effective sedation to ensure patient comfort and procedural safety. This study compared the efficacy and safety of Midazolam and Fentanyl versus Dexmedetomidine and Fentanyl sedation during upper endoscopy, it was conducted as a preliminary investigation to guide the design of a future definitive trial.</p> Methods <p>A prospective pilot study was conducted at An-Najah National University Hospital, Palestine, from October 2021 to January 2022. Sixty-eight ASA I and II outpatients aged 18–60 years were assigned to receive either Dexmedetomidine (0.3 mcg/kg) or Midazolam (0.05&#xa0;mg/kg), both with Fentanyl (1 mcg/kg). Sedation depth was assessed using the Ramsay Sedation Scale (RSS) and recovery by the Post-Anesthesia Recovery Score (PARS). All procedures were performed by the same endoscopist; sedation was administered by an independent anesthesiologist.</p> Results <p>Dexmedetomidine led to significantly higher patient and endoscopist satisfaction, shorter recovery time (9.5 ± 1.1 vs. 22.4 ± 7.7&#xa0;min, <i>p</i> &lt; 0.05), and reduced anxiety and discomfort. Adverse effects were fewer but not significantly different. Vital signs remained stable in both groups.</p> Conclusion <p>Dexmedetomidine and Fentanyl offers a more effective and better-tolerated sedation option than Midazolam and Fentanyl for upper endoscopy, with higher satisfaction and faster recovery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A pilot study comparing Dexmedetomidine and Midazolam in sedation for upper endoscopy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Ibrahim Ghoul,
  • Aidah Alkaissi,
  • Wael Sadaqa,
  • Qusay Abdoh,
  • Shadi Khelfa,
  • Raneen Nazzal,
  • Muath Almasri,
  • Mohammed F. Hayek,
  • Baraa J. S. Hijazi,
  • Amro Adas

摘要

Background

Upper gastrointestinal endoscopy often causes discomfort and anxiety, requiring effective sedation to ensure patient comfort and procedural safety. This study compared the efficacy and safety of Midazolam and Fentanyl versus Dexmedetomidine and Fentanyl sedation during upper endoscopy, it was conducted as a preliminary investigation to guide the design of a future definitive trial.

Methods

A prospective pilot study was conducted at An-Najah National University Hospital, Palestine, from October 2021 to January 2022. Sixty-eight ASA I and II outpatients aged 18–60 years were assigned to receive either Dexmedetomidine (0.3 mcg/kg) or Midazolam (0.05 mg/kg), both with Fentanyl (1 mcg/kg). Sedation depth was assessed using the Ramsay Sedation Scale (RSS) and recovery by the Post-Anesthesia Recovery Score (PARS). All procedures were performed by the same endoscopist; sedation was administered by an independent anesthesiologist.

Results

Dexmedetomidine led to significantly higher patient and endoscopist satisfaction, shorter recovery time (9.5 ± 1.1 vs. 22.4 ± 7.7 min, p < 0.05), and reduced anxiety and discomfort. Adverse effects were fewer but not significantly different. Vital signs remained stable in both groups.

Conclusion

Dexmedetomidine and Fentanyl offers a more effective and better-tolerated sedation option than Midazolam and Fentanyl for upper endoscopy, with higher satisfaction and faster recovery.